[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635808":3},{"organization":4,"outcomesModule":7,"designInfo":68,"detailedDescription":67,"studyPopulation":71,"armGroups":72,"interventions":82,"overallOfficials":88,"centralContacts":91,"locations":99,"responsibleParty":118,"collaborators":67,"id":120,"slug":121,"hasResults":122,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":122,"sex":128,"minAge":129,"maxAge":67,"enrollmentInfo":130,"targetDuration":67,"studyType":133,"phases":67,"briefSummary":134,"conditions":135,"keywords":137,"overallStatus":102,"whyStopped":67,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":148},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":62,"otherOutcomes":67},[9,13,15,17,19,21,23,27,30,32,34,36,38,40,42,44,46,48,50,52,54,56,58],{"measure":10,"description":11,"timeFrame":12},"Participant blood pressure (both systolic and diastolic)","Group 1 only","Baseline",{"measure":14,"description":11,"timeFrame":12},"Date of diagnosis of hypertrophic cardiomyopathy",{"measure":16,"description":11,"timeFrame":12},"Hypertrophic cardiomyopathy genetic testing results",{"measure":18,"description":11,"timeFrame":12},"Family history of hypertrophic cardiomyopathy",{"measure":20,"description":11,"timeFrame":12},"Family history of Sudden Cardiac Death (SCD)",{"measure":22,"description":11,"timeFrame":12},"Participant comorbidities (cardiovascular and non-cardiovascular )",{"measure":24,"description":25,"timeFrame":26},"Type of prior surgeries and procedures","Group 1 only. Prior surgeries and procedures include: Septal Reduction Therapy (SRT), surgeries (valve repair\u002Fplacement, left atrial appendage ligation), placement of devices (Implantable Cardioverter Defibrillator (ICD), pacemaker and cardiac resynchronization therapy) or atrial fibrillation\u002Fflutter ablation","Baseline and up to week 24",{"measure":28,"description":11,"timeFrame":29},"Participant New York Heart Association (NYHA) class category","Baseline, and at weeks 4, 8, 12, 24",{"measure":31,"description":11,"timeFrame":29},"Change in participant New York Heart Association (NYHA) class from baseline",{"measure":33,"description":11,"timeFrame":29},"Duration of mavacamten treatment",{"measure":35,"description":11,"timeFrame":29},"Number of mavacamten dose titrations",{"measure":37,"description":11,"timeFrame":29},"Type of mavacamten dose tritration",{"measure":39,"description":11,"timeFrame":29},"Clinical reason for mavacamten dose titration",{"measure":41,"description":11,"timeFrame":29},"Clinical reason for mavacamten treatment discontinuation",{"measure":43,"description":11,"timeFrame":29},"Left Ventricular Ejection Fraction (LVEF) recovery after mavacamten discontinuation if discontinued due to LVEF\u003C50%,",{"measure":45,"description":11,"timeFrame":29},"Time from mavacamten discontinuation to Left Ventricular Ejection Fraction (LVEF) recovery",{"measure":47,"description":11,"timeFrame":29},"Clinical reason for temporary mavacamten treatment interuption",{"measure":49,"description":11,"timeFrame":29},"Time to temporary mavacamten treatment interruption",{"measure":51,"description":11,"timeFrame":29},"Left Ventricular Ejection Fraction (LVEF) recovery after mavacamten interruption if the interruption was due to LVEF\u003C50%",{"measure":53,"description":11,"timeFrame":29},"Time from mavacamten treatment interruption to Left Ventricular Ejection Fraction (LVEF) recovery",{"measure":55,"description":11,"timeFrame":29},"Time to mavacamten treatment resumption",{"measure":57,"description":11,"timeFrame":29},"Type of hypertrophic cardiomyopathy (HCM) background therapy prescribed",{"measure":59,"description":60,"timeFrame":61},"Type of changes to hypertrophic cardiomyopathy (HCM) background therapy","Group 1 only. Type of changes include initiation, switching, discontinuation, augmentation, dose titration","At baseline, weeks 4, 8, 12, 24",[63],{"measure":64,"description":65,"timeFrame":66},"Perspectives on treatment preference, and the eligibility, onboarding and implementation of mavacamten as assessed by feedback collated through structured physician interviews","Group 2 only","Up to week 24",null,{"allocation":67,"interventionModel":67,"interventionModelDescription":67,"primaryPurpose":67,"observationalModel":69,"timePerspective":70,"maskingInfo":67},"COHORT","OTHER","The study population will consist of adults that have been diagnosed with obstructive hypertrophic cardiomyopathy (HCM) and have received treatment with mavacamten and their treating clinicians from participating community-based sites in the US.",[73,78],{"label":74,"type":67,"description":75,"interventionNames":76},"Group 1","Participants with obstructive hypertrophic cardiomyopathy (oHCM) receiving mavacamten",[77],"Drug: Mavacamten",{"label":79,"type":67,"description":80,"interventionNames":81},"Group 2","Physicians treating patients diagnosed with obstructive hypertrophic cardiomyopathy (oHCM)",[77],[83],{"type":84,"name":85,"description":86,"armGroupLabels":87,"otherNames":67},"DRUG","Mavacamten","According to the product label",[74,79],[89],{"name":5,"affiliation":5,"role":90},"STUDY_DIRECTOR",[92,97],{"name":93,"role":94,"phone":95,"phoneExt":67,"email":96},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":98,"role":94,"phone":67,"phoneExt":67,"email":67},"First line of the email MUST contain NCT # and Site #.",[100],{"facility":101,"status":102,"city":103,"state":104,"zip":105,"country":106,"countryCode":107,"cosmosGeoPoint":108,"geoPoint":113,"contacts":114},"Adelphi Real World","RECRUITING","Bollington","Macclesfield","SK10 5JB","United Kingdom","UK",{"type":109,"coordinates":110},"Point",[111,112],-2.10963,53.29446,{"lat":112,"lon":111},[115],{"name":116,"role":94,"phone":117,"phoneExt":67,"email":67},"USA Generic Country, Site 0001","0000000000",{"type":119,"investigatorFullName":67,"investigatorTitle":67,"investigatorAffiliation":67,"oldNameTitle":67,"oldOrganization":67},"SPONSOR","100635808","mavacamten-outcomes-in-hypertrophic-cardiomyopathy-hcm-and-the-associated-patient-and-physician-experiences-in-the-us-100635808",false,"NCT07557498","Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US","Mavacamten Real-World OutcomeS and the Associated PAtient and Physician ExpeRienCe With Hypertrophic CardioMyopathy in the United States (US) Community","SPARC-HCM","Inclusion Criteria:\n\nPhase I: retrospective chart review\n\nFor inclusion in the study, participants must meet ALL of the following criteria:\n\n* Are an adult aged 18 or over at baseline\n* Have a confirmed diagnosis of obstructive hypertrophic cardiomyopathy (HCM)\n* Have been prescribed mavacamten for obstructive HCM at one of the study sites between 28th April 2022 and 31st December 2024\n* Have not ever been enrolled in any interventional clinical trial involving any cardiac myosin inhibitor (enrollment in observational studies is permitted)\n* Are not enrolled in any interventional clinical trial at study baseline\n\nPhase II: patient survey • Participants must meet all inclusion criteria of Phase I: retrospective chart review and be able to read and understand English and have access to computer or smartphone to complete the survey\n\nExclusion Criteria:\n\n• None with the proviso that all inclusion criteria are met.","ALL","18 Years",{"count":131,"type":132},362,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to understand the real-world clinical outcomes and treatment patterns of adults with obstructive hypertrophic cardiomyopathy (HCM) treated with mavacamten, and to understand patient and physician experiences with mavacamten treatment, in the US community-based practice",[136],"Obstructive Hypertrophic Cardiomyopathy (oHCM)",[138],"Obstructive Hypertrophic cardiomyopathy (oHCM)","2026-04-23",{"date":141,"type":142},"2026-04-29","ACTUAL",{"date":144,"type":142},"2026-01-15",{"date":146,"type":132},"2027-06-17",{"name":5,"class":6},1]